Conduit Pharmaceuticals Inc.
CDT
$0.6201
-$0.16-20.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 100.65% | -25.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.61% | 72.32% | |||
| Operating Income | 11.61% | -72.32% | |||
| Income Before Tax | 62.76% | -20.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 62.76% | -20.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 62.76% | -20.03% | |||
| EBIT | 11.61% | -72.32% | |||
| EBITDA | 19.93% | -- | |||
| EPS Basic | 71.00% | -1.70% | |||
| Normalized Basic EPS | 53.71% | 10.78% | |||
| EPS Diluted | 71.00% | -1.70% | |||
| Normalized Diluted EPS | 53.71% | 10.78% | |||
| Average Basic Shares Outstanding | 28.40% | 18.02% | |||
| Average Diluted Shares Outstanding | 28.40% | 18.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||